Restoration of podocyte structure and improvement of chronic renal disease in transgenic mice overexpressing renin.
BACKGROUND
Proteinuria is a major marker of the decline of renal function and an important risk factor of coronary heart disease. Elevated proteinuria is associated to the disruption of slit-diaphragm and loss of podocyte foot processes, structural alterations that are considered irreversible. The objective of the present study was to investigate whether proteinuria can be reversed and to identify the structural modifications and the gene/protein regulation associated to this reversal.


RESULTS
We used a novel transgenic strain of mouse (RenTg) that overexpresses renin at a constant high level. At the age of 12-month, RenTg mice showed established lesions typical of chronic renal disease such as peri-vascular and periglomerular inflammation, glomerular ischemia, glomerulosclerosis, mesangial expansion and tubular dilation. Ultrastructural analysis indicated abnormal heterogeneity of basement membrane thickness and disappearance of podocyte foot processes. These structural alterations were accompanied by decreased expressions of proteins specific of podocyte (nephrin, podocin), or tubular epithelial cell (E-cadherin and megalin) integrity. In addition, since TGFbeta is considered the major pro-fibrotic agent in renal disease and since exogenous administration of BMP7 is reported to antagonize the TGFbeta-induced phenotype changes in kidney, we have screened the expressions of several genes belonging in the TGFbeta/BMP superfamily. We found that the endogenous inhibitors of BMPs such as noggin and Usag-1 were several-fold activated inhibiting the action of BMPs and thus reinforcing the deleterious action of TGFbeta.Treatment with an AT1 receptor antagonist, at dose that did not decrease arterial pressure, gradually reduced albuminuria. This decrease was accompanied by re-expression of podocin, nephrin, E-cadherin and megalin, and reappearance of podocyte foot processes. In addition, expressions of noggin and Usag-1 were markedly decreased, permitting thus activation of the beneficial action of BMPs.


CONCLUSIONS
These findings show that proteinuria and alterations in the expression of proteins involved in the integrity and function of glomerular and renal epithelial phenotype are reversible events when the local action of angiotensin II is blocked, and provide hope that chronic renal disease can be efficiently treated.
Huby
Anne-Cécile
AC
INSERM UMR 702, Paris, France.
Rastaldi
Maria-Pia
MP
Caron
Kathleen
K
Smithies
Oliver
O
Dussaule
Jean-Claude
JC
Chatziantoniou
Christos
C
D000818:Animals; D001483:Base Sequence; D017931:DNA Primers; D004195:Disease Models, Animal; D006973:Hypertension / Q000150:complications; D007150:Immunohistochemistry; D007676:Kidney Failure, Chronic / Q000209:etiology / Q000235:genetics / Q000473:pathology*; D051379:Mice; D008822:Mice, Transgenic; D046529:Microscopy, Electron, Transmission; D050199:Podocytes / Q000166:cytology*; D012083:Renin / Q000235:genetics / Q000378:metabolism*
D017931:DNA Primers; D012083:Renin
Am J Physiol Renal Physiol. 2008 May;294(5):F1238-48
18322023
Hypertension. 2007 Jul;50(1):212-8
17515450
Nat Med. 2003 Jul;9(7):964-8
12808448
Acta Diabetol. 2012 Dec;49 Suppl 1:S15-24
18008027
J Am Soc Nephrol. 2003 Nov;14(11):2833-42
14569093
PLoS Med. 2008 Oct 21;5(10):e207
18942886
Am J Nephrol. 2001 Jan-Feb;21(1):78-83
11275639
Endocrinology. 2009 Feb;150(2):871-8
18927221
Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3106-11
14978280
J Am Soc Nephrol. 2003 May;14(5):1132-44
12707384
Cell. 1996 Aug 23;86(4):599-606
8752214
Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8248-52
12034874
Am J Pathol. 2003 Nov;163(5):1937-47
14578193
Acta Pharmacol Sin. 2007 Nov;28(11):1810-8
17959033
Am J Pathol. 2008 May;172(5):1391-402
18385519
J Biol Chem. 2005 Mar 4;280(9):8094-100
15591043
J Am Soc Nephrol. 2001 Dec;12(12):2701-2710
11729239
Kidney Int. 2008 Jan;73(2):181-91
17943079
Am J Pathol. 2009 Mar;174(3):797-807
19164508
FASEB J. 2007 Oct;21(12):3355-68
17554073
Am J Nephrol. 2004 Sep-Oct;24(5):488-96
15353911
J Am Soc Nephrol. 2001 May;12(5):941-948
11316852
Am J Physiol. 1997 Oct;273(4):F563-74
9362334
Pediatr Nephrol. 2008 Sep;23(9):1395-8
18446379
Diabetologia. 2002 Jun;45(6):890-8
12107734
Hypertension. 2003 Nov;42(5):937-44
14569001
J Am Soc Nephrol. 2006 Dec;17(12):3374-81
17093065
Kidney Int. 2008 Oct;74(7):873-8
18650796
Am J Hypertens. 1996 Nov;9(11):1077-83
8931832
J Clin Invest. 2006 Jan;116(1):70-9
16341262
Kidney Int. 2008 Sep;74(5):585-95
18509316
Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4602-7
11904385
Am J Pathol. 2006 Apr;168(4):1073-85
16565484
Nephrol Dial Transplant. 2006 Apr;21(4):881-8
16384829
Am J Pathol. 1990 Dec;137(6):1323-32
2260622
Am J Physiol Renal Physiol. 2008 Jul;295(1):F137-44
18434388
Am J Pathol. 2009 Jan;174(1):21-33
19056849
Am J Physiol Cell Physiol. 2008 Apr;294(4):C1034-45
18256274
Am J Pathol. 2008 Sep;173(3):631-42
18688035
Circulation. 1999 Nov 2;100(18):1901-8
10545435
FASEB J. 2004 May;18(7):926-8
15033924